Eradivir is a privately held, clinical-stage biotech that leverages its proprietary BAiT (Bispecific Antigenic immuno-Therapy) platform to create small-molecule drugs with antibody-like efficacy. Its lead program, EV25, is in a Phase 2a human influenza challenge study, with results expected in the coming weeks. A second molecule, EV148, is being advanced toward IND-enabling studies for respiratory syncytial virus (RSV). By swapping the platform’s targeting ligand, the company believes it can expand into other viral diseases and cancer. Management emphasizes a capital-efficient approach, having raised its first $30 million in milestone-based tranches to limit dilution. The recent financing has already funded completion of the EV25 Phase 2a study and will bankroll preclinical work on EV148. Headquartered in West Lafayette, Indiana, Eradivir positions itself at the intersection of small-molecule convenience and immunotherapy potency.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2025